Spanish skincare specialist Almirall (BME: ALM) has announced positive results from a real-world study of Ilumetri (tildrakizumab) at the 25th World Congress of Dermatology.
The IL-23-targeting antibody is designed to block proinflammatory agents without severely impacting on the rest of the immune system.
Out-licensed by Indian drugmaker Sun Pharmaceutical (BSE: 524715), Almirall has rights to develop and commercialize the product for psoriasis in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze